Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 264-036-0 | CAS number: 63225-53-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From: 26 Apr 2021 to 03 Aug 2021
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 021
- Report date:
- 2021
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- 1997
- Deviations:
- no
- GLP compliance:
- yes
- Remarks:
- According to Chem VwV-GLP Nr. 5.3/OECD Guidance
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- 2-[[(butylamino)carbonyl]oxy]ethyl acrylate
- EC Number:
- 264-036-0
- EC Name:
- 2-[[(butylamino)carbonyl]oxy]ethyl acrylate
- Cas Number:
- 63225-53-6
- Molecular formula:
- C10H17NO4
- IUPAC Name:
- 2-[[(butylamino)carbonyl]oxy]ethyl acrylate
Constituent 1
Test animals
- Strain:
- Wistar
- Remarks:
- Species: Han
- Details on species / strain selection:
- The Wistar Han rat was chosen as the animal model for this study as it is an accepted rodent species for toxicity testing by regulatory agencies.
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
Research Models and Services Germany GmbH
Sandhofer Weg 7, 97633 Sulzfeld, Germany
- Age at study initiation: 6-10 weeks
- Weight at study initiation: 164-201 g
- Assigned to test groups randomly: Yes
- Fasting period before study: No
- Housing: Group housed in Makrolon Type IV, with wire mesh top
- Diet: 2018C Teklad Global 18% protein rodent diet (certified), ad libitum; Supplier: Envigo Teklad Diets, Madison, Wisconsin, United States of America
- Water: tap water
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-24°C
- Humidity (%): 45-65%
- Air changes (per hr): at least 8
- Photoperiod (hrs dark / hrs light): 12 /12
IN-LIFE DATES: From: 26 April 2021To: 03 August 2021
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- - Vehicle(s)/solvent(s) used: Corn oil
- Justification for choice of solvent/vehicle: The vehicle was chosen due to its relative non-toxicity for the animals and ability to form a suitable dosing formulation
- Amount of vehicle (if gavage or dermal): 10 mL/kg bw
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
On the day of the experiment, the test item was freshly formulated in corn oil. The formulations were prepared at room temperature, and applied to the animals within 15 minutes
after preparation - Duration of treatment / exposure:
- Not applicable
- Frequency of treatment:
- Single dose
- Post exposure period:
- Pre-Experiment on Toxicity: The animals were treated once orally with the test item and examined for acute toxic symptoms at intervals of approx. 0-1 h, 2-4 h, 5-6 h, 24 h, 30 h, and 48 h after administration of the test item.
Main study: The animals of all dose groups, except the positive control group, were examined for acute toxic symptoms at intervals of around 0-1 h, 2-4 h, 5-6 h, 24 h, and/or 48 h after
administration of the test item. Sampling of the bone marrow was conducted at low, mid and high doses at 24 h and then at the high dose only at 48 h
Doses / concentrationsopen allclose all
- Dose / conc.:
- 500 mg/kg bw (total dose)
- Dose / conc.:
- 1 000 mg/kg bw (total dose)
- Dose / conc.:
- 2 000 mg/kg bw (total dose)
- No. of animals per sex per dose:
- Pre experiment on toxicity: 2 males/2 females
Main study: 6 males per dose - Control animals:
- yes, concurrent vehicle
- other:
- Positive control(s):
- Cyclophosphamide dissolved in sterile water
- Justification for choice of positive control(s): Identified as a suitable positive control in the guidelines
- Route of administration: oral
- Doses / concentrations: 20 mg/kg bw
Examinations
- Tissues and cell types examined:
- The femora were removed, the epiphyses were cut off and the marrow was flushed out with foetal calf serum using a syringe. The nucleated cells were separated from the erythrocytes using the method of Romagna et. al.
- Details of tissue and slide preparation:
- Tissue preparation: The cell suspensions were passed through a column consisting of α-cellulose and cellulose. The columns were then washed with Hank’s buffered saline. The cell suspension was centrifuged at 1500 rpm (390 x g) for 10 minutes and the supernatant was discarded.
Slide preparation: A small drop of the re-suspended cell pellet was spread on a slide. The smear was air-dried and then stained with May-Grünwald/Giemsa. Cover slips were mounted with EUKITT. At least one slide was made from each bone marrow sample.
Evaluation of the slides was performed using NIKON microscopes with 100x oil immersion objectives. At least 4000 polychromatic erythrocytes (PCE) per animal were analysed for micronuclei. To describe a cytotoxic effect the ratio between polychromatic and normochromatic erythrocytes was determined in the same sample and expressed in polychromatic erythrocytes per total erythrocytes. The analysis was performed with coded slides.
Bioanalysis was performed (report number S21-02411-L1) by Eurofins Agroscience Services EAG Laboratories GmbH.
Six additional male rats were assigned to 2 groups in order to be treated as satellite animals for plasma sampling. These animals were treated once with the test item at the maximum tolerated dose level, as determined within the range finding experiment. All animals were sampled twice by retroorbital puncture (eyes alternating). A maximum blood volume of 1.5 mL was withdrawn during the first sampling time point. The first sampling was performed under light isoflurane anaesthesia. The second, terminal sampling was performed under deep CO2 anaesthesia, and the animals were humanely euthanized after sampling by cervical dislocation whilst they were are in deep anaesthesia.
Blood sampling scheme:
Group 1: 1st sampling before first treatment '2nd sampling and termination 1 hour after application
Group 2: 1st sampling 0.5 hours after application, 2nd sampling and termination 4 hours after application.
The blood of the animals was collected in tubes containing K3-EDTA. The blood samples were centrifuged at 10’000 rpm for about 5 minutes to obtain plasma samples. The obtained plasma was divided in duplicates of about 0.2 mL each. - Evaluation criteria:
- The test substance is classified as positive in the assay if:
a) At least one of the treatment groups exhibits a statistically significant increase in the frequency of micronucleated immature erythrocytes compared with the concurrent
negative control,
b) This increase is dose-related at least at one sampling time when evaluated with an
appropriate trend test, and
c) Any of these results are outside the distribution of the historical negative control data
(e.g., Poisson-based 95% control limits)
The study was considered valid if the following criteria were met:
• the concurrent negative control is considered acceptable for addition to the laboratory historical control database (should ideally be within the 95% control limits of the distribution of the historical negative control database)
• at least 5 animals per group can be evaluated.
• the appropriate number of doses and cells will be analysed.
• PCE to erythrocyte ratio is not less than 20% of the negative control.
• The positive control shows a statistically significant increase of micronucleated PCEs compared to the negative control and is compatible to those in the historical positive control database. - Statistics:
- Statistical significance at the five per cent level (p < 0.05) was evaluated by means of the non-parametric Mann-Whitney test using the validated statistical program RScript Wilcoxon_2.Rnw. The Holm-Bonferroni Adjustment method was used to correct for the Familywise error rate of multiple comparisons.
Results and discussion
Test results
- Key result
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF RANGE-FINDING STUDY
- Dose range: 2000 mg/kg bw
- Clinical signs of toxicity in test animals: Decreased activity. No substantial differences between sexes in toxicity were observed, so that only male animals were used in the main experiment.
- Evidence of cytotoxicity in tissue analysed: None
- Rationale for exposure: It is generally recommended to use the maximum tolerated dose or the highest dose that can be formulated and administered reproducibly or 2000 mg/kg bw as the upper limit for nontoxic test items.
- Harvest times: Three adequately spaced dose levels spaced by a factor of 2 were administered and samples of bone marrow were collected at the central sampling interval 24 h after treatment.
RESULTS OF DEFINITIVE STUDY
- Induction of micronuclei (for Micronucleus assay): 4000 polychromatic erythrocytes (PCEs) per animal were scored for micronuclei. Results are shown in Tables 1, 2, 3, 4, 5 and 6
- Ratio of PCE/NCE (for Micronucleus assay): The ratio between polychromatic and normochromatic erythrocytes was determined in the same sample and reported as the number of PCEs per total erythrocytes. Results are shown in Tables 1, 2, 3, 4, 5 and 6
- Appropriateness of dose levels and route: As estimated by a pre-experiment at 2000 mg/kg bw (the maximum guideline-recommended dose) was suitable as highest treatment dose. The animals treated with the test item and the vehicle control did not exhibit any clinical symptoms.
- Statistical evaluation: In comparison to the corresponding vehicle controls there was no statistically significant or biologically relevant enhancement in the frequency of the detected micronuclei at any preparation interval and dose level after administration of the test item. The mean values of micronuclei observed after treatment with the test substance were near to the value of the vehicle control group as shown in Table 1, 2, 3, 4, 5 and 6.
A linear regression (least squares, calculated using the validated statistical program RScript
LM_v02.Rnw) was performed to assess a possible dose dependent increase of mean micronuclei values. The mean number of micronuclei obtained for the groups treated with the test item was compared to the vehicle control group. A trend is judged as significant whenever the p-value (probability value) is below 0.05. A p-value of 0.1964 was obtained, demonstrating that there was no dose dependent increase of mean micronuclei values.
A bioanalysis of the test item in plasma (phase number S21-02411-L1) was performed. The method had been successfully validated by procedural recovery samples for determination of the test substance with an LOQ of 0.10 mg/L and up to 10 mg/L in rat plasma according to the guidance document SANTE/2020/12830 rev. 1 of the European Commission. With regard to selectivity, accuracy and precision, the analytical method was applied successfully for the analytical set when analysing the samples of the study. In all plasma samples of animals treated with the test substance at a concentration of 2000 mg/kg bw, however, the residues of the test substance were below the Limit of Detection (i.e., <0.03 mg/L). Rapid hydrolysis of the test substance was suspected as the most probable underlying reason for the missing proof of exposure.
Any other information on results incl. tables
Micronuclei in polychromatic erythrocytes (PCE) and relationship PCE per 4000 erythrocytes scoring 24 hours after treatment
Table 1: Vehicle Control
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Corn Oil |
0 |
1 |
4000 |
11 |
0.28 |
771 |
271 |
0.649 |
|
2 |
4000 |
2 |
0.05 |
934 |
434 |
0.535 |
|||
3 |
4000 |
8 |
0.20 |
707 |
207 |
0.707 |
|||
4 |
4000 |
12 |
0.30 |
812 |
312 |
0.616 |
|||
5 |
4000 |
7 |
0.18 |
823 |
323 |
0.608 |
|||
6 |
4000 |
4 |
0.10 |
845 |
345 |
0.592 |
|||
|
|
|
|
|
|
|
|||
Mean |
7.3 |
0.19 |
815.3 |
315.3 |
0.618 |
||||
SD |
3.9 |
0.10 |
75.8 |
75.8 |
0.058 |
Table 2: Test Item - Low Dose Group
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Dose 1 |
500 |
7 |
4000 |
5 |
0.13 |
801 |
301 |
0.624 |
|
8 |
4000 |
6 |
0.15 |
691 |
191 |
0.724 |
|||
9 |
4000 |
9 |
0.23 |
686 |
186 |
0.729 |
|||
10 |
4000 |
9 |
0.23 |
725 |
225 |
0.690 |
|||
11 |
4000 |
10 |
0.25 |
737 |
237 |
0.678 |
|||
12 |
4000 |
6 |
0.15 |
718 |
218 |
0.696 |
|||
|
|
|
|
|
|
|
|||
Mean |
7.5 |
0.19 |
726.3 |
226.3 |
0.690 |
||||
SD |
2.1 |
0.05 |
41.6 |
41.6 |
0.038 |
Table 3: Test Item - Medium Dose Group
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Dose 2 |
1000 |
13 |
4000 |
7 |
0.18 |
682 |
182 |
0.733 |
|
14 |
4000 |
9 |
0.23 |
782 |
282 |
0.639 |
|||
15 |
4000 |
5 |
0.13 |
730 |
230 |
0.685 |
|||
16 |
4000 |
12 |
0.30 |
751 |
251 |
0.666 |
|||
17 |
4000 |
15 |
0.38 |
790 |
290 |
0.633 |
|||
18 |
4000 |
9 |
0.23 |
719 |
219 |
0.695 |
|||
|
|
|
|
|
|
|
|||
Mean |
9.5 |
0.24 |
742.3 |
242.3 |
0.675 |
||||
SD |
3.6 |
0.09 |
40.6 |
40.6 |
0.037 |
Table 4: Test Item - High Dose Group
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Dose 3 |
2000 |
19 |
4000 |
9 |
0.23 |
739 |
239 |
0.677 |
|
20 |
4000 |
9 |
0.23 |
769 |
269 |
0.650 |
|||
21 |
4000 |
6 |
0.15 |
1129 |
629 |
0.443 |
|||
22 |
4000 |
4 |
0.10 |
784 |
284 |
0.638 |
|||
23 |
4000 |
14 |
0.35 |
910 |
410 |
0.549 |
|||
24 |
4000 |
13 |
0.33 |
1184 |
684 |
0.422 |
|||
|
|
|
|
|
|
|
|||
Mean |
9.2 |
0.23 |
919.2 |
419.2 |
0.563 |
||||
SD |
3.9 |
0.10 |
193.7 |
193.7 |
0.110 |
Table 5: Positive Control
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Positive |
20 |
25 |
4000 |
55 |
1.38 |
767 |
267 |
0.652 |
|
26 |
4000 |
105 |
2.63 |
948 |
448 |
0.527 |
|||
27 |
4000 |
76 |
1.90 |
1104 |
604 |
0.453 |
|||
28 |
4000 |
63 |
1.58 |
1115 |
615 |
0.448 |
|||
29 |
4000 |
63 |
1.58 |
1080 |
580 |
0.463 |
|||
30 |
4000 |
42 |
1.05 |
1281 |
781 |
0.390 |
|||
|
|
|
|
|
|
|
|||
Mean |
67.3 |
1.69 |
1049.2 |
549.2 |
0.489 |
||||
SD |
21.6 |
0.54 |
174.3 |
174.3 |
0.091 |
Micronuclei in polychromatic erythrocytes (PCE) and relationship PCE per 4000 erythrocytes scoring 48 hours after treatment
Table 6: Test Item - High Dose Group
Test Group |
Dose mg/kg b.w. |
Animal No. |
Micronuclei in Polychromatic Erythrocytes (PCE) |
Evaluation 500 PCE in |
|||||
No. PCE |
No. MN/4000 PCE |
% |
Total No |
NCE per total Ery |
Ratio PCE/Total Ery |
||||
Dose 3 |
2000 |
31 |
4000 |
15 |
0.38 |
625 |
125 |
0.800 |
|
32 |
4000 |
10 |
0.25 |
820 |
320 |
0.610 |
|||
33 |
4000 |
9 |
0.23 |
766 |
266 |
0.653 |
|||
34 |
4000 |
10 |
0.25 |
963 |
463 |
0.519 |
|||
35 |
4000 |
7 |
0.18 |
969 |
469 |
0.516 |
|||
36 |
4000 |
8 |
0.20 |
970 |
470 |
0.515 |
|||
|
|
|
|
|
|
|
|||
Mean |
9.8 |
0.25 |
852.2 |
352.2 |
0.602 |
||||
SD |
2.8 |
0.07 |
141.3 |
141.3 |
0.113 |
Animal Weights
Dose Group |
Animal No. |
Animal weights before treatment |
Animal weights before sacrifice |
||||||||||
Initial Weight [g] |
Mean [g] |
SD [g] |
Range |
Initial Weight [g] |
Mean [g] |
SD [g] |
Range |
||||||
Vehicle Control |
1 |
179.0 |
179.0 |
5.4 |
169.3 |
- |
185.2 |
185.3 |
186.2 |
6.3 |
174.8 |
- |
193.7 |
2 |
185.2 |
193.7 |
|||||||||||
3 |
169.3 |
174.8 |
|||||||||||
4 |
182.6 |
189.8 |
|||||||||||
5 |
179.4 |
186.3 |
|||||||||||
6 |
178.7 |
187.2 |
|||||||||||
500 mg/kg b.w. |
7 |
191.4 |
180.6 |
10.1 |
165.7 |
- |
191.9 |
199.8 |
187.1 |
9.7 |
171.5 |
- |
199.8 |
8 |
181.0 |
186.6 |
|||||||||||
9 |
165.7 |
171.5 |
|||||||||||
10 |
191.9 |
194.6 |
|||||||||||
11 |
178.8 |
186.0 |
|||||||||||
12 |
174.5 |
184.0 |
|||||||||||
1000 mg/kg b.w. |
13 |
187.0 |
187.8 |
9.3 |
175.6 |
- |
200.6 |
194.9 |
193.0 |
10.8 |
177.9 |
- |
205.7 |
14 |
196.7 |
203.9 |
|||||||||||
15 |
200.6 |
205.7 |
|||||||||||
16 |
175.6 |
177.9 |
|||||||||||
17 |
183.4 |
184.8 |
|||||||||||
18 |
183.8 |
190.8 |
|||||||||||
2000 mg/kg b.w. |
19 |
169.8 |
186.6 |
11.6 |
169.8 |
- |
196.6 |
160.8 |
184.6 |
16.6 |
160.8 |
- |
201.9 |
20 |
194.6 |
201.9 |
|||||||||||
21 |
192.3 |
187.0 |
|||||||||||
22 |
192.1 |
185.8 |
|||||||||||
23 |
196.6 |
201.8 |
|||||||||||
24 |
173.9 |
170.0 |
|||||||||||
Positive Control |
25 |
182.6 |
178.7 |
4.6 |
170.4 |
- |
183.5 |
188.7 |
184.1 |
6.8 |
171.2 |
- |
188.7 |
26 |
170.4 |
171.2 |
|||||||||||
27 |
178.7 |
188.2 |
|||||||||||
28 |
178.4 |
185.7 |
|||||||||||
29 |
178.8 |
182.1 |
|||||||||||
30 |
183.5 |
188.5 |
|||||||||||
2000 mg/kg b.w. |
31 |
193.1 |
184.8 |
12.3 |
164.3 |
- |
198.7 |
198.5 |
188.0 |
11.3 |
174.6 |
- |
199.4 |
32 |
198.7 |
199.4 |
|||||||||||
33 |
181.9 |
174.9 |
|||||||||||
34 |
179.7 |
186.4 |
|||||||||||
35 |
164.3 |
174.6 |
|||||||||||
36 |
190.8 |
194.4 |
Animal Weights
Dose Group |
Animal No. |
Animal weights before treatment |
Animal weights before sacrifice |
||||||||||
Initial Weight [g] |
Mean [g] |
SD [g] |
Range |
Initial Weight [g] |
Mean [g] |
SD [g] |
Range |
||||||
Vehicle Control |
1 |
179.0 |
179.0 |
5.4 |
169.3 |
- |
185.2 |
185.3 |
186.2 |
6.3 |
174.8 |
- |
193.7 |
2 |
185.2 |
193.7 |
|||||||||||
3 |
169.3 |
174.8 |
|||||||||||
4 |
182.6 |
189.8 |
|||||||||||
5 |
179.4 |
186.3 |
|||||||||||
6 |
178.7 |
187.2 |
|||||||||||
500 mg/kg b.w. |
7 |
191.4 |
180.6 |
10.1 |
165.7 |
- |
191.9 |
199.8 |
187.1 |
9.7 |
171.5 |
- |
199.8 |
8 |
181.0 |
186.6 |
|||||||||||
9 |
165.7 |
171.5 |
|||||||||||
10 |
191.9 |
194.6 |
|||||||||||
11 |
178.8 |
186.0 |
|||||||||||
12 |
174.5 |
184.0 |
|||||||||||
1000 mg/kg b.w. |
13 |
187.0 |
187.8 |
9.3 |
175.6 |
- |
200.6 |
194.9 |
193.0 |
10.8 |
177.9 |
- |
205.7 |
14 |
196.7 |
203.9 |
|||||||||||
15 |
200.6 |
205.7 |
|||||||||||
16 |
175.6 |
177.9 |
|||||||||||
17 |
183.4 |
184.8 |
|||||||||||
18 |
183.8 |
190.8 |
|||||||||||
2000 mg/kg b.w. |
19 |
169.8 |
186.6 |
11.6 |
169.8 |
- |
196.6 |
160.8 |
184.6 |
16.6 |
160.8 |
- |
201.9 |
20 |
194.6 |
201.9 |
|||||||||||
21 |
192.3 |
187.0 |
|||||||||||
22 |
192.1 |
185.8 |
|||||||||||
23 |
196.6 |
201.8 |
|||||||||||
24 |
173.9 |
170.0 |
|||||||||||
Positive Control |
25 |
182.6 |
178.7 |
4.6 |
170.4 |
- |
183.5 |
188.7 |
184.1 |
6.8 |
171.2 |
- |
188.7 |
26 |
170.4 |
171.2 |
|||||||||||
27 |
178.7 |
188.2 |
|||||||||||
28 |
178.4 |
185.7 |
|||||||||||
29 |
178.8 |
182.1 |
|||||||||||
30 |
183.5 |
188.5 |
|||||||||||
2000 mg/kg b.w. |
31 |
193.1 |
184.8 |
12.3 |
164.3 |
- |
198.7 |
198.5 |
188.0 |
11.3 |
174.6 |
- |
199.4 |
32 |
198.7 |
199.4 |
|||||||||||
33 |
181.9 |
174.9 |
|||||||||||
34 |
179.7 |
186.4 |
|||||||||||
35 |
164.3 |
174.6 |
|||||||||||
36 |
190.8 |
194.4 |
Historical Control Data (Oct 2014 - Dec 2020)
Vehicle Controls (%) |
Male animals |
|
min |
0.025 |
|
max |
0.750 |
|
mean |
0.255 |
|
95% Ctr. Limit |
0.001 |
0.509 |
SD |
0.127 |
|
2x SD |
0.254 |
|
Range of individual animal micronuclei values* |
1 - 30 |
|
No° indiv. values |
240 |
Positive Controls (%) |
Male animals |
|
min |
0.450 |
|
max |
4.525 |
|
mean |
1.718 |
|
95% Ctr. Limit |
-0.086 |
3.522 |
SD |
0.902 |
|
2x SD |
1.804 |
|
Range of individual animal micronuclei values* |
18 - 181 |
|
No° indiv. values |
161 |
*per 4000 Polychromatic Erythrocytes
Historical Control Data (Oct 2014 - Dec 2020)
Vehicle Controls (%) |
Male animals |
|
min |
0.025 |
|
max |
0.750 |
|
mean |
0.255 |
|
95% Ctr. Limit |
0.001 |
0.509 |
SD |
0.127 |
|
2x SD |
0.254 |
|
Range of individual animal micronuclei values* |
1 - 30 |
|
No° indiv. values |
240 |
Positive Controls (%) |
Male animals |
|
min |
0.450 |
|
max |
4.525 |
|
mean |
1.718 |
|
95% Ctr. Limit |
-0.086 |
3.522 |
SD |
0.902 |
|
2x SD |
1.804 |
|
Range of individual animal micronuclei values* |
18 - 181 |
|
No° indiv. values |
161 |
*per 4000 Polychromatic Erythrocytes
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.